InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$86.60

2026-10-16

Market Cap

$49.9B

Volume

4.0M

52-Wk High

$96.29

52-Wk Low

$72.67

Trailing PE

49.8

P/S

7.66

Gross Margin

78.0%

Net Margin

15.4%

ROE

10%

ROIC

10%

Piotroski

6/9

Altman Z

12.3

1-Yr Return

+19.2%

5-Yr Return

+17.0%

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

SectorHealthcareIndustryMedical - DevicesExchangeNYSEMarket Cap$49.9BEmployees16,000 (SEC-filed)CEOBernard J. ZovighianIPO2000-03-27CountryUS

One Edwards Way, Irvine, CA 92614 · Tel 949 250 2500 · edwards.com

INSIDERSTREET SCORE65 / 100Street mean $104.00 (3 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$19M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · EW +19.2% · S&P 500 +15.9% · spread +3.3pp

7 Years vs S&P 500 · EW +17.0% · S&P 500 +189.9% · spread -172.8pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE65of 100

Score Breakdown

Profitability	64/100
Growth	33/100
Momentum	64/100
Quality	82/100
Earnings Quality	75/100
Balance Sheet	94/100
Value	36/100
Risk (safety)	100/100
Overall	64.7/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
BSX	67
DXCM	81
SYK	74
MDT	64
ZBH	60
ABT	57
EW	65

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 67 in 25 Q1, latest 65 — -3 since. Fell in 2 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY65 / 100IS Score 64.7 / 100 · -2.5 from peak of 67

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTURELEAN BULLISHTechnical Score 56 / 100 · Power +12 · 14 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 65 and price structure at 56 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 64.7	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 57 → 63 → 65 → 65	the direction matters more than the level
Technical vote share back above 50%	now 64%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,331 → now 1,331	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)2 buys2026-05-01

Insider Buys (180d)0none disclosed

ETF Funds (30d)1348 up / 1077 downnet +271 funds

Institutions Added (13F)46managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,331 · latest 1,331 (+0 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	1,331	525.3M	$46.8B	91.1%
2026 Q1	1,285	504.0M	$39.7B	87.4%
2025 Q4	1,309	504.8M	$42.3B	87.6%
2025 Q3	1,246	491.4M	$37.8B	85.3%
2025 Q2	1,252	502.6M	$38.9B	87.2%
2025 Q1	1,199	505.2M	$36.3B	87.7%
2024 Q4	1,220	502.2M	$36.6B	87.1%
2024 Q3	1,186	479.8M	$31.2B	83.2%
2024 Q2	1,286	493.0M	$44.5B	85.5%
2024 Q1	1,267	487.1M	$45.4B	84.5%
2023 Q4	1,234	480.6M	$36.2B	83.4%
2023 Q3	1,208	491.9M	$33.7B	85.3%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Lippis Daniel J.	CVP, TAVR	2026-10-08	EXERCISE	619	$0.04M	40,653
Lippis Daniel J.	CVP, TAVR	2026-10-08	SELL	619	$0.05M	40,034
Lippis Daniel J.	CVP, TAVR	2026-10-08	EXERCISE	619	$0.04M	3,095
Markowitz Wayne	CVP, JAPAC	2026-09-14	TAX W/H	568	$0.05M	19,371
Dahl Andrew M.	SVP, Corporate Controller	2026-09-13	TAX W/H	253	$0.02M	14,615
Markowitz Wayne	CVP, JAPAC	2026-09-11	TAX W/H	355	$0.03M	19,939
Chopra Daveen	CVP, TMTT, Surgical & IHFM	2026-09-11	TAX W/H	398	$0.03M	43,926
Lippis Daniel J.	CVP, TAVR	2026-09-11	EXERCISE	619	$0.04M	40,653

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	36	221,381	$18.6M	Counted
M — Exercises (paired A/D)	21	216,316	$7.9M	None — mechanics
F — Tax withholding	31	85,791	$7.0M	None — compensation
G — Gifts	5	37,194	—	None
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$18.6M36 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-08-31	Dahl Andrew M.	544	$0.0M
2026-08-28	Bruls Annette	2,644	$0.2M
2026-08-26	Markowitz Wayne	1,240	$0.1M
2026-08-26	Chopra Daveen	31,800	$2.9M
Trailing 12 mo	32 filings	437,020	$37M

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Filed	Form	Reporting person	% of class	Shares
2026-04-29	SCHEDULE 13G	Vanguard Capital Management	7.54%	43.5M sh
2025-10-17	SCHEDULE 13G/A	BlackRock, Inc.	7.50%	44.3M sh
2025-08-12	SCHEDULE 13G/A	Wellington Investment Advisors Holdings LLP	3.40%	19.8M sh
2025-01-30	SCHEDULE 13G/A	The Vanguard Group	11.72%	69.1M sh

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-05-01	2026-06-11
Ro Khanna	House	SELL	$1,001 - $15,000	2026-01-13	2026-02-10
Josh Gottheimer	House	SELL	$1,001 - $15,000	2025-11-19	2025-12-30
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-27	2026-07-20
Markwayne Mullin	Senate	SELL	$15,001 - $50,000	2024-08-20	2024-09-19
Markwayne Mullin	Senate	SELL	$15,001 - $50,000	2024-08-20	2024-09-18

House 12-Mo6 trades1 purchases

Senate 12-Mo1 trades1 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,285

13F Shares504M87.4% of shares out

New / Closed117 / 117positions, QoQ

Increased / Reduced454 / 452positions, QoQ

Put/Call (13F)1.00option positions

Free Float98.8%569M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Ninety One Uk Ltd	11.9M	$1.0B
Assenagon Asset Management S.A.	2.7M	$235M
Birch Hill Investment Advisors Llc	723,022	$62M
Seilern Investment Management Ltd	589,732	$51M
Ninety One North America, Inc.	582,170	$50M
Ninety One Sa	265,013	$23M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.1%	$1.6B
VTI	0.1%	$1.6B
VTSAX	0.1%	$1.6B
VSMPX	0.1%	$1.6B
VFINX	0.1%	$1.3B
VFIAX	0.1%	$1.3B

13F Filers Holding EW — quarterly

Institutional Put/Call — quarterly

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session56.3%2026-10-15

20-Day Avg51.3%50-day 46.3%

TrendRising20d vs 50d

By Market CenterQ: 56% · N: 71% · B: 53%latest session

Weekly Notional ($B)

Where EW Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	4.3M	65 sh
Ubsa Ubs Ats	3.9M	65 sh
Sgmt Sigma X2	2.8M	61 sh
Mstx Ms Trajectory Cross (Ats-1)	2.5M	61 sh
Ebxl Level Ats	2.4M	43 sh
Pure Purestream	2.3M	32 sh

Where a dollar of Edwards Lifesciences Corporation revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$3.5B	58%
Europe	$1.5B	25%
Rest of World	$652M	11%
JAPAN	$355M	6%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

EW (live moat model)Peer median: BSX · DXCM · SYK · MDT · ZBH

Component scores from the live moat model. Peer median illustrative.

Moat score 59/100 — Narrow; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Bernard J. Zovighian	Chief Executive Officer & Director
Theodora Mistras	Corporate Vice President & Chief Financial Officer
Annette Maria Bruls	Corporate Vice President of EMEA, Canada, & Latin America
Donald E. Bobo Jr.	Corporate Vice President of Strategy & Corporate Development

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)5 of 6recent quarters

Avg Surprise+5.5%

Next Report2026-11-04

Income Quality1.71OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+19.3%	+2.9%	-6.9%	+8.6%	+11.5%
Gross profit	+21.9%	+5.2%	-5.8%	+8.8%	+9.7%
Operating income	+24.3%	+5.7%	-16.2%	-3.4%	+18.7%
Net income	+82.5%	+1.3%	-7.9%	+197.7%	-74.3%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	5.2	5.4	5.0	5.4	6.1
Cost of revenue	1.2	1.2	1.0	1.1	1.3
Gross profit	4.0	4.2	4.0	4.3	4.7
R&D expense	0.9	0.9	1.0	1.1	1.1
SG&A expense	1.5	1.6	1.6	1.8	2.1
Operating income	1.6	1.7	1.4	1.4	1.6
EBITDA	1.9	2.0	1.5	1.7	1.4
D&A	0.2	0.2	0.1	0.2	0.2
Pretax income	1.7	1.8	1.4	1.5	1.3
Income tax	0.2	0.2	0.2	0.2	0.2
Net income	1.5	1.5	1.4	4.2	1.1
Diluted EPS ($)	2.38	2.44	2.30	6.97	1.83
Diluted shares (M)	631	624	609	599	586

Operating CF$2B

CapEx$0B

Free cash flow$1B

SBC$0B

Buybacks$1B

Net cash change$-0B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	0.8	1.1	3.0	2.9
ST investments	0.4	0.5	0.9	1.3
Receivables (net)	0.7	0.8	0.7	0.9
Total current assets	3.1	4.0	6.3	6.7
PP&E (net)	1.7	1.7	1.8	1.9
Goodwill + intangibles	1.4	1.5	3.0	2.9
Total assets	8.3	9.4	13.1	13.7
Accounts payable	0.2	0.2	0.2	0.2
Short-term debt	0.0	0.0	0.0	0.0
Deferred revenue	0.0	0.0	0.1	0.0
Total current liabilities	1.0	1.2	1.5	1.8
Long-term debt	0.6	0.6	0.6	0.6
Total liabilities	2.5	2.6	3.0	3.4
Shareholders' equity	5.8	6.7	10.1	10.3

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	1.5	1.4	4.2	1.1
D&A	0.1	0.1	0.2	0.2
Stock-based compensation	0.1	0.1	0.2	0.2
Working capital change	(0.4)	(0.5)	(0.3)	0.2
Operating cash flow	1.2	0.9	0.5	1.6
Capital expenditures	(0.3)	(0.3)	(0.3)	(0.3)
Investing cash flow	0.3	0.2	2.3	(0.7)
Buybacks	(1.7)	(0.9)	(1.2)	(0.9)
Dividends paid	0.0	0.0	0.0	0.0
Debt issuance / (repay)	(0.0)	(0.0)	0.0	0.0
Financing cash flow	(1.6)	(0.7)	(1.0)	(1.0)
Free cash flow	1.0	0.6	0.3	1.3

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	28.9%	26.1%	22.5%	50.1%	10.5%	10%
ROA	19.1%	18.1%	15.9%	37.2%	8.0%	7.2%
ROIC	28.1%	27.7%	22.9%	18.6%	19.7%	10.2%
Gross margin	76.6%	78.3%	79.3%	79.5%	78.1%	78.0%
Operating margin	30.8%	31.6%	28.5%	25.3%	27.0%	28.1%
Net margin	28.7%	28.3%	28.0%	76.7%	17.7%	15.4%
EBITDA margin	36.1%	36.4%	30.6%	31.7%	23.6%	24.3%
FCF margin	26.8%	17.7%	12.0%	5.3%	22.0%	—
VALUATION
P/E	54.47	30.21	33.00	10.48	46.35	49.8
P/B	14.03	7.92	6.96	4.37	4.80	4.7
P/S	15.65	8.54	8.79	8.01	8.17	7.66
P/FCF	58.39	48.22	73.51	150.79	37.15	34.8
EV/EBITDA	43.31	23.47	28.69	23.13	33.12	30.1
EV/Revenue	15.50	8.44	8.61	7.41	7.59	7.3
Earnings yield	1.8%	3.3%	3.0%	9.5%	2.2%	2.01%
FCF yield	1.7%	2.1%	1.4%	0.7%	2.7%	2.87%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	3.08	3.03	3.38	4.18	3.72	4.52
Quick ratio	2.38	2.17	2.62	3.45	3.09	3.77
Debt / equity	0.12	0.12	0.10	0.07	0.07	0.07
Debt / assets	8.1%	8.3%	7.3%	5.4%	5.1%	5.1%
Net debt / EBITDA	-0.41	-0.27	-0.60	-1.87	-2.53	-1.39
Interest coverage	231.00	842.62	—	—	—	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.66	0.64	0.60	0.49	0.45	0.47
Receivables turnover	9.54	8.79	7.44	7.90	9.57	6.8
DSO (days)	38	42	49	46	38	54
DPO (days)	60	63	61	61	58	54
Cash conversion cycle	206	228	269	303	284	288
GROWTH (YoY)
Revenue growth	19.3%	2.9%	-2.2%	3.6%	11.2%	—
Net income growth	82.5%	1.3%	-7.9%	197.5%	-74.4%	—
EPS growth	82.5%	3.8%	-6.4%	205.8%	-74.0%	—
FCF growth	116.7%	-32.0%	-34.0%	-53.9%	360.5%	—
PER SHARE ($)
EPS (diluted, TTM)	2.38	2.47	2.31	7.07	1.84	1.74
Book value / share	9.23	9.42	10.96	16.93	17.77	18.61
Revenue / share	8.28	8.73	8.68	9.24	10.43	11.30
FCF / share	2.22	1.55	1.04	0.49	2.29	2.49
Cash / share	2.32	1.97	2.69	6.73	7.27	7.38
SHAREHOLDER RETURN & SCORES
Buyback yield	0.6%	3.8%	1.9%	2.4%	0.3%	0.88%
Altman Z-Score	21.00	14.03	13.28	11.44	11.49	12.3
Piotroski F-Score	8	6	6	6	6	6/9
Beneish M-Score	-2.42	-2.29	-2.06	-1.20	-2.45	-2.66

Model	Score	Zone	Note
Piotroski F-Score	6 / 9	Middling
Altman Z-Score	12.3	Safe (>2.99)	Safe
Income quality	1.71	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.66	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.71
Interest burden	1.00
Operating margin	21.8%
Asset turnover	0.48×
Financial leverage	1.29×
= ROE	9%

Growth Quality (live)	Value
Revenue stability	0.77
Earnings stability	0.07
Earnings persistence	0.50
Revenue CAGR 3y	6.3%
EPS CAGR 3y	-8.6%
FCF CAGR 3y	28.1%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.88%

Dividend Yield0.00%none paid

Total Shareholder Return0.58%cash yield

SBC / Revenue2.6%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
BSX	$64.3B	17.9	15%	16.7%	+13.5%	8/9	-54.6%
DXCM	$32.5B	33.2	38%	19.0%	+15.5%	9/9	+29.7%
SYK	$113.0B	30.3	17%	19.4%	+8.5%	9/9	-20.2%
MDT	$121.2B	23.2	11%	15.1%	+9.8%	9/9	+3.0%
ZBH	$18.1B	23.0	6%	9.1%	+8.6%	6/9	—
ABT	$181.5B	33.7	11%	7.4%	+8.1%	5/9	—
PEN	$12.6B	78.4	11%	8.9%	+17.6%	6/9	—
SNN	$12.2B	19.0	22%	9.8%	+11.5%	8/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

49 Analysts

Str Sell (0)Sell (0)Hold (16)Buy (33)Str Buy (0)

Mean Target (qtr)$104.003 targets

Target vs. Price+20.1%last-quarter mean

Next Report2026-11-04street $0.74

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$6.77B	$6.81B / $6.67B	$3.00	$3.05 / $2.97	16
FY2027	$7.42B	$7.50B / $7.22B	$3.39	$3.46 / $3.29	16
FY2028	$8.20B	$8.59B / $7.86B	$3.81	$3.89 / $3.66	7

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Quarter	$104.00	+20.1%	3
Last Year	$96.31	+11.2%	49
All Time	$97.29	+12.3%	106

Rolling mean of published targets vs. last close $86.60. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B

DCF

3/5

ROE

3/5

ROA

5/5

Debt/Eq

3/5

P/E

1/5

P/B

2/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

EW +19.2% vs S&P 500 +15.9% — spread +3.3pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$86.46	+0.14	+0.16%	Above
SMA 50	$88.42	-1.82	-2.06%	Below
SMA 200	$85.14	+1.46	+1.71%	Above
EMA 9	$86.41	+0.19	+0.22%	Above
EMA 21	$86.63	-0.03	-0.03%	Below
EMA 50	$87.33	-0.73	-0.84%	Below
EMA 200	$85.43	+1.17	+1.37%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

TECHNICAL VERDICTLEAN BULLISHPower Score +1214 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%56

Momentum 25%70

Volume 20%56

Volatility 10%50

Patterns 15%38

This Week64% bullishof 11 price-based votes

4 Weeks Ago18%+46 pts since

12 Weeks Ago18%+46 pts since

ReadImprovingweek-over-week trajectory

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Price vs SMA 20$86.46

Price vs SMA 50$88.42

Price vs SMA 200$85.14

EMA 9/21 Cross86.4/86.6

SMA 50/200Golden

ADX DirectionADX 13

Supertrend$91

Parabolic SAR$83

SMA Slope-0.080

RSI49.2

Stochastic K/D78/70

StochRSI K/D84/77

Williams %R-30

CCI47

TSI vs Signal-5.8

CMO-1.7

ROC1.70%

OBV SignalDistrib

Chaikin MF0.060

MFI49

Force Index0M

Elder Ray Bull1.74

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 70

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$87.35 / $89.16 / $90.22	S1 / S2	$86.29 / $84.48
Bollinger (20,2)	$84.12 – $88.80	Squeeze	ON
52-wk range	$72.42 – $96.29	Off 52-wk high	-10.1%
ATR (14)	$2.16 (2.5%)	Historical vol	22.8%

+1.6%Jan55%

+0.4%Feb55%

+2.6%Mar81%

+3.3%Apr65%

+0.9%May65%

+4.2%Jun75%

-0.0%Jul55%

+1.2%Aug60%

+1.1%Sep45%

-2.5%Oct45%

+2.9%Nov70%

+4.2%Dec60%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	EW	S&P 500
Weekly volatility (σ, 1y)	3.43%	1.83%
Best / worst week (1y)	+9.1% / -6.8%	—
Max drawdown (5y, monthly)	-47.6%	—
1-week VaR (95%)	-4.6%	—
Beta (5y)	0.85	1.00

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

EW EQUITY WEATHER (LIVE)RAINY · -18

Trend-23

Momentum+21

Volume-44

Volatility-30

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 140 stories, weekly buckets, −1 to +1.

Overall-17.9+2.4 vs industry

Trend-22.9-0.8 vs industry

Momentum+21.3+43.3 vs industry

Volume-43.9-38.9 vs industry

Reading	EW	Medical - Devices n=524	Healthcare n=5,272	All US symbols n=70,435
Overall	-17.9	-20.2	-24.0	-20.5
Trend	-22.9	-22.1	-25.6	-21.3
Momentum	+21.3	-22.0	-28.5	-15.8
Volume	-43.9	-5.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Mr. Zovighian Chief Executive Officer and Di	$17.5M	55% equity+incentive
Mr. Ullem Corporate Vice President, Chief Fi	$6.1M	52% equity+incentive
Mr. Wood Former Corporate Vice President and	$4.9M	52% equity+incentive
Mr. Chopra Corporate Vice President, Transca	$4.7M	55% equity+incentive
Mr. Bobo Corporate Vice President, Strategy	$4.2M	51% equity+incentive

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Pillar (live disclosure scores)	Score
Environmental	52
Social	63
Governance	60
Composite ESG	58

Composite ESG Trend

Filed	8-K contents	Items
2026-08-28	Officer/Director Change	5.02
2026-07-23	Earnings Release; Exhibits	2.02,9.01
2026-05-08	Officer/Director Change; Shareholder Vote; Exhibits	5.02,5.07,9.01
2026-05-04	Officer/Director Change; Regulation FD	5.02,7.01
2026-04-23	Earnings Release; Exhibits	2.02,9.01
2026-02-10	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2026-01-12	Regulation FD Disclosure; Financial Statements and Exhibits	7.01,9.01
2025-10-30	Departure/Election of Directors; Appointment of Officers; Regulation F	5.02,7.01,9.01

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-21 to 2026-07-23
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	109 rows · 1999 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-28 to 2026-10-08
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2025-01-30 to 2026-04-29
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Edwards Lifesciences Corporation (EW)

Institutions holding — 12 quarters

Edwards Lifesciences Corporation (EW)

Monthly Net Insider Flow (000 shares)

Signal Summary

Edwards Lifesciences Corporation (EW)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding EW — quarterly

Institutional Put/Call — quarterly

Edwards Lifesciences Corporation (EW)

Where EW Trades in the Dark

Edwards Lifesciences Corporation (EW)

3.8 · Employees (SEC filings)

Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW)

Balance Sheet — Full

Cash Flow Statement — Full

Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW)

Street Price Target — Trajectory

Third-Party Composite Rating

Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW)

Family Scores (site weights)

Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW)